The global nanoparticles - metal & metal oxides market in healthcare was estimated at USD 25.86 billion in 2016. The presence of a substantial number of metal nanoparticle based medicines that are currently approved by the U.S. FDA is one of the key factors for estimated revenue. In addition, there are a number of products in clinical & investigational phases of development with anticipated positive results, thereby driving industrial attractiveness of the field.
The versatile nature of these particles enables them in serving several biomedical applications such as thermal ablation, radiotherapy enhancement, highly sensitive diagnostic assays, and drug & gene delivery. Technological advancements pertaining to the reduction of adverse events associated with the usage of these products are anticipated to influence progress in the coming years.
U.S. nanoparticles - metal & metal oxides market in healthcare, by application, 2013 - 2025 (USD Billion)
Currently, biologists and scientists are involved in conducting research activities to enhance understanding of metallic nanoparticles in order to reduce the toxicity issues associated with their usage. Resultant developments are expected to accelerate the production and sale of such molecules throughout the forecast period.
The pharmaceutical industry is an ever-evolving marketplace with dynamic regulatory standards, rising manufacturing costs, and growing demand for sophisticated & effective health solutions. These issues are constantly exerting pressure on therapeutics producers to meet the untapped demand of the population. Owing to the aforementioned factors, nanoparticle technologies are recognized as the source of lucrative revenue generation as they offer significant potential to help disease management.
The presence of numerous projects in the R&D phase is expected to drive market growth. by augmenting the future product portfolio for this market. Furthermore, the presence of government-backed programs such as the National Nanotechnology Initiative (NNI), launched in 2000, that provides support to co-ordinate advance R&D of projects for nanomedicine development are factors reinforcing the high revenue potential of the said market space.
Gold nanoparticles held the largest share owing to the huge adoption of these in human therapeutic development. Factors such as better compatibility, low toxicity & tunable stability, and small dimensions are supportive of this steady rise in the adoption of gold nanoparticles.
Moreover, gold nanocages coated with the temperature-sensitive polymer are applicable in targeted drug delivery that on interaction with near-infrared radiations, release effectors. These effectors are useful in providing efficient control and monitoring for drug interaction, thus driving adoption in various imaging, disease monitoring, diagnosis, and drug delivery applications ranging from DNA to cellular level.
However, alumina based molecules are expected to grow at a lucrative rate as a consequence of rising interest of researchers for its therapeutic applications with respect to targeted cell destruction. Moreover, aluminum oxide in combination with polymeric membranes is studied for enhancement of drug delivery owing to its high porosity property displayed in the membranes.
In-vivo imaging is estimated to account for the largest revenue share as a consequence of rising application of nanoshells such as Au3Cu1 that are reported to provide enhanced contrast for blood vessels for its potential application for in vivo MR angiography. Also, AuNPs serve as probes that enable in-vivo as well as in-vitro visual monitoring of protease and proteases inhibitor activities.
Owing to ongoing research for drug delivery applications using nanotechnology, targeted delivery is projected to exhibit the fastest YoY growth. Development of photo-modulated nanoshells for drug delivery is anticipated to enhance the uptake of technology.
Nanoparticles - metal & metal oxides market in healthcare, by region, 2016 (%)
North America accounted for the largest share of revenue in 2016 owing to the presence of effective regulatory guidelines in the region regarding therapeutic development. This region is witnessing inter-country collaboration on the use and production of nanoparticles. For instance, the U.S. and Canada cooperated on nanomaterials under the Regulatory Cooperation Council (RCC). As a result, a conference to conclude the nanotechnology work plan of the region, was held in Washington, DC in January 2014.
Asia Pacific is expected to sustain the fastest growth in this market owing to the rising investment in nanoparticle development coupled with increase in the number of clinical studies to understand the toxicity of these nanoparticles. Asian countries have been observed as the potential nanotechnology hubs of the not so distant future, which in turn, has resulted into the rise in research activities on the applications of nanomolecules.
Major entities operating in this market include Pfizer Inc., Nanobiotix, nanoComposix, AstraZeneca, Merck KGaA, Immunolight LLC, Nanospectra Biosciences, Inc, Brigham, and Women's Hospital (BWH). Pharma-biotech market involves huge capital investment and is research intensive in nature. Market entities are engaged in the development of more sophisticated analysis tools for their detection and characterization.
Product innovations in human therapeutics and rising global demand for robust disease treatment solutions are expected to drive the global market of nanoparticles. A large number of ongoing clinical studies coupled with the presence of a large number of products in pipeline is further expected to boost revenue, as Nano biotechnology has attracted high levels of R&D investments for nanoparticle-based chemotherapeutic agents & drugs.
Attribute |
Details |
Base year for estimation |
2016 |
Actual estimates/Historic data |
2013 - 2016 |
Forecast period |
2017 - 2025 |
Market representation |
Revenue in USD Billion & CAGR from 2017 to 2025 |
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Country scope |
U.S., Canada, UK, Germany, Japan, China, Brazil, South Africa. |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you are looking for specific or additional market information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at regional & country level and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2013 to 2025. For the purpose of this report, Grand View Research has segmented the Nanoparticles - metal & metal oxides market in healthcare on the basis of type, application, and region:
Type Outlook (Revenue, USD Billion; 2013 - 2025)
Gold Nanoparticles
Silver Nanoparticles
Iron Oxide Nanoparticles
Alumina Nanoparticles
Gadolinium Oxide Nanoparticles
Others
Application Outlook (Revenue, USD Billion; 2013 - 2025)
In-vivo Imaging
Targeted Drug Delivery
Proton Therapy
In-vitro Assays
Cell & Phantom Imaging
Regional Outlook (Revenue, USD Billion; 2013 - 2025)
North America
The U.S.
Canada
Europe
Germany
UK
Asia Pacific
Japan
China
Latin America
Brazil
Middle East and Africa (MEA)
South Africa
b. The global nanoparticles metal and metal oxides market size was estimated at USD 36.07 billion in 2019 and is expected to reach USD 40.73 billion in 2020.
b. The global nanoparticles metal and metal oxides market is expected to grow at a compound annual growth rate of 13.78% from 2018 to 2025 to reach USD 80.74 billion by 2025.
b. North America dominated the nanoparticles metal and metal oxides market with a share of 41.5% in 2019. This is attributed to the presence of effective regulatory guidelines in the region regarding therapeutic development and inter-country collaboration for the production of nanoparticles.
b. Some key players operating in the telemedicine market include Pfizer Inc., Nanobiotix, nanoComposix, AstraZeneca, Merck KGaA, Immunolight LLC, Nanospectra Biosciences, Inc, Brigham and Women's Hospital (BWH).
b. Key factors that are driving the market growth include presence of a substantial number of metal nanoparticle based medicines, versatile nature of these nanoparticles, and technological advancements.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."